Insulin resistance, postprandial GLP-1 and adaptive immunity are the main predictors of NAFLD in a homogeneous population at high cardiovascular risk

Nutr Metab Cardiovasc Dis. 2016 Jul;26(7):623-629. doi: 10.1016/j.numecd.2016.01.011. Epub 2016 Apr 14.

Abstract

Background and aims: The role of the different factors associated with fatty liver is still poorly defined. We evaluated the relationships between liver fat content (LF) and metabolic, inflammatory and nutritional factors in a homogeneous cohort of individuals at high cardio-metabolic risk.

Methods and results: In 70 individuals with high waist circumference and at least one more criterion for metabolic syndrome enrolled in a nutritional intervention study, LF was evaluated at baseline by hepatic/renal echo intensity ratio (H/R), together with dietary habits (7-day dietary record), insulin sensitivity and β-cell function (fasting and OGTT-derived indices), fasting and postprandial plasma GLP-1 and lipoproteins, and plasma inflammatory markers. H/R correlated positively with fasting and OGTT plasma glucose and insulin concentrations, HOMA-IR and β-cell function, and IL-4, IL-17, IFN-γ, TNF-α, FGF and GCSF plasma concentrations (p < 0.05 for all), and negatively with insulin sensitivity (OGIS), dietary, polyphenols and fiber (p < 0.05 for all). By multiple stepwise regression analysis, the best predictors of H/R were OGIS (β = -0.352 p = 0.001), postprandial GLP-1 (β = -0.344; p = 0.001), HDL-cholesterol (β = -0.323; p = 0.002) and IFN-γ (β = 0.205; p = 0.036).

Conclusion: A comprehensive evaluation of factors associated with liver fat, in a homogeneous population at high cardio-metabolic risk, indicated a pathogenic combination of the same pathways underlying the atherosclerotic process, namely whole body insulin sensitivity and inflammation. The higher predictive value of postprandial variables suggests that liver fat is essentially a postprandial phenomenon, with a relevant role possibly played by GLP-1.

Registration number for clinical trials: NCT01154478.

Keywords: GLP-1; HDL; IFN-g; Inflammation; Insulin resistance; NAFLD.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adaptive Immunity*
  • Adult
  • Aged
  • Biomarkers / blood
  • Blood Glucose / metabolism
  • Cardiovascular Diseases / blood
  • Cardiovascular Diseases / etiology*
  • Cardiovascular Diseases / immunology
  • Cardiovascular Diseases / prevention & control
  • Cholesterol, HDL / blood
  • Cross-Sectional Studies
  • Diet Records
  • Feeding Behavior
  • Female
  • Glucagon-Like Peptide 1 / blood*
  • Humans
  • Inflammation Mediators / blood
  • Insulin / blood
  • Insulin Resistance*
  • Interferon-gamma / blood
  • Italy
  • Liver / diagnostic imaging
  • Liver / immunology
  • Liver / metabolism*
  • Liver / physiopathology
  • Male
  • Metabolic Syndrome / blood
  • Metabolic Syndrome / diet therapy
  • Metabolic Syndrome / etiology*
  • Metabolic Syndrome / immunology
  • Middle Aged
  • Multivariate Analysis
  • Non-alcoholic Fatty Liver Disease / blood
  • Non-alcoholic Fatty Liver Disease / diet therapy
  • Non-alcoholic Fatty Liver Disease / etiology*
  • Non-alcoholic Fatty Liver Disease / immunology
  • Nutritional Status
  • Postprandial Period*
  • Regression Analysis
  • Risk Assessment
  • Risk Factors
  • Time Factors

Substances

  • Biomarkers
  • Blood Glucose
  • Cholesterol, HDL
  • IFNG protein, human
  • Inflammation Mediators
  • Insulin
  • Interferon-gamma
  • Glucagon-Like Peptide 1

Associated data

  • ClinicalTrials.gov/NCT01154478